The bacterial enzyme MurA catalyzes the transfer of enolpyruvate from phosp
hoenolpyruvate (PEP) to uridine diphospho-N-acetylglucosamine (UNAG), which
is the first committed step of bacterial cell wall biosynthesis. From high
-throughput screening of a chemical library, three novel inhibitors of the
Escherichia coli MurA enzyme were identified: the cyclic disulfide RWJ-3981
, the purine analog RWJ-140998, and the pyrazolopyrimidine RWJ-110192. When
MurA was preincubated with inhibitor, followed by addition of UNAG and PEP
, the 50% inhibitory concentrations (IC(50)s) were 0.2 to 0.9 muM, compared
to 8.8 muM for the known MurA inhibitor, fosfomycin. The three compounds e
xhibited MICs of 4 to 32 mug/ml against Staphylococcus aureus; however, the
inhibition of DNA, RNA, and protein synthesis in addition to peptidoglycan
synthesis by all three inhibitors indicated that antibacterial activity wa
s not due specifically to MurA inhibition. The presence of UNAG during the
MurA and inhibitor preincubation lowered the IC50 at least fivefold, sugges
ting that, like fosfomycin, the three compounds may interact with the enzym
e in a specific fashion that is enhanced by UNAG. Ultrafiltration and mass
spectrometry experiments suggested that the compounds were tightly, but not
covalently, associated with MurA. Molecular modeling studies demonstrated
that the compounds could fit into the site occupied by fosfomycin; exposure
of MurA to each compound reduced the labeling of MurA by tritiated fosfomy
cin. Taken together, the evidence indicates that these inhibitors may bind
noncovalently to the MurA enzyme, at or near the site where fosfomycin bind
s.